Intarcia Therapeutics (United States)

Recent papers from Intarcia Therapeutics (United States)

1. Re-entering the cell: Is the intracellular space the true therapeutic niche for aptamers?Molecular Therapy — Nucleic Acids · 2026
2. Targeting IL-22 activity to the gut epithelium confers disease benefit without provoking skin inflammation 2258200The Journal of Immunology · 2026
3. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem HelixThe Journal of Infectious Diseases · 2026
4. The immunogenicity database collaborative: a standardized, publicly available database for clinical immunogenicity observations and insightsFrontiers in Immunology · 2026
5. The non-viral delivery era has begun, with challenges aheadCell and Gene Therapy Insights · 2026
6. Chemically induced skin tumors arise from long-lived stem cells of the upper hair follicleScience · 2026
7. Abstract ND07: TRI-611, a potent, selective, CNS-penetrant ALK molecular glue degrader for the treatment of ALK-fusion protein positive non-small cell lung cancerCancer Research · 2026
8. Design of Cyclic Vinyl Sulfones as WRN Covalent Inhibitors from Noncovalent Binders.2026
9. Abstract 5787: TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins and leads to regression of ALK TKI-refractory tumorsCancer Research · 2026
10. Abstract 5789: Discovery of a selective molecular glue degrader of CCNE1 for the treatment of CCNE1-amplified solid tumors and CDK4/6i-resistant HR+/HER2- breast cancersCancer Research · 2026
11. Abstract 2660: AV-P138-ADC (ARR-002), a novel MUC16/NaPi2b dual-target tetravalent ADC, for the treatment of ovarian and endometrial cancersCancer Research · 2026
12. Abstract 2406: A novel covalent BRD4 degrader-HER2-targeting antibody-drug conjugate (DAC) overcomes trastuzumab deruxtecan resistance in HER2-positive cancers.Cancer Research · 2026
13. Abstract 4618: TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastasesCancer Research · 2026
14. Abstract 7631: Predicting and preventing cancer stemness in low Earth orbitCancer Research · 2026
15. Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyBlood Advances · 2026
16. Abstract A054: AMP-410: A VEGF-dependent conditional 4-1BB agonist drives localized antitumor immunity with high therapeutic index across multiple tumor typesCancer Immunology Research · 2026
17. The Immunogenicity Database Collaborative (IDC): A Standardized, Publicly Available Database for Clinical Immunogenicity Observations and Insights2025
18. Discovery of a small molecule TLR3 agonist adjuvantThe Medicine Forum · 2025
19. Proteome-wide in silico screening for human protein-protein interactions2025
20. First-in-Human Study of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix2025